Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons
Author(s) -
Jordi Pujols,
Samuel PeñaDíaz,
Diana F. Lázaro,
Francesca Peccati,
Francisca Pinheiro,
Danilo González,
Anita Čarija,
Susanvarro,
María Conde-Giménez,
Jesús García,
Salvador Guardiola,
Ernest Giralt,
Xavier Salvatella,
Javier Sancho,
Mariona Sodupe,
Tiago F. Outeiro,
Esther Dalfó,
Salvador Ventura
Publication year - 2018
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1804198115
Subject(s) - fibril , dopaminergic , neurite , dementia with lewy bodies , chemistry , parkinson's disease , microbiology and biotechnology , in vitro , alpha synuclein , protein aggregation , intracellular , caenorhabditis elegans , biophysics , biology , neuroscience , biochemistry , pathology , dopamine , disease , medicine , dementia , gene
Significance Parkinson’s disease is characterized by the accumulation of amyloid deposits in dopaminergic neurons, mainly composed of the protein α-synuclein. The disordered nature of α-synuclein and its complex aggregation reaction complicate the identification of molecules able to prevent or revert the formation of these inclusions and the subsequent neurodegeneration. By exploiting a recently developed high-throughput screening assay, we identified SynuClean-D, a small compound that inhibits α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom